Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

Beyond chronic myelogenous leukemia : Potential role for imatinib in Philadelphia-negative myeloproliferative disorders

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Current patient management of chronic myeloid leukemia in Latin America : A study by the Latin American Leukemia Net (LALNET)

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia : A randomized trial of frontline high-dose imatinib mesylate with or without pegylated

Monitoring molecular response in chronic myeloid leukemia

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

Finite-time convergent gradient flows with applications to network consensus

Global and robust formation-shape stabilization of relative sensing networks

Promising Approaches in Acute Leukemia

Phase I study of liposomal daunorubicin in patients with acute leukemia

Cooperative detection of areas of rapid change in spatial fields

Deployment of an unreliable robotic sensor network for spatial estimation

6 Natural history and staging of chronic myelogenous leukaemia

Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

509 The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies